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The Movement disorder 
associated with NMDAR 
antibody-encephalitis is 
complex and characteristic: an 
expert video-rating study
IntroductIon
N-methyl-D-aspartate receptor antibody- 
mediated encephalitis (NMDAR-AbE) is 
an increasingly recognised and treatable 
encephalitis, with a predilection for chil-
dren and young adults.1 2 As earlier immu-
notherapy improves outcomes, timely and 
accurate recognition of NMDAR-AbE is a 
major clinical aim.2
The characteristic polysymptomatic 
presentation of NMDAR-AbE includes 
early neuropsychiatric deficits with 
seizures, autonomic disturbance, reduced 
consciousness and a movement disorder 
(MD).1 2 This MD, seen in around 90% 
of cases, can be the presenting feature, 
particularly in children,1 and is typically 
hyperkinetic with limb plus orofacial 
involvement.1–5 To date, elegant detailed 
descriptions exist in a few patients.4 
However, small series have used highly 
variable phenomenological descrip-
tions.1–5 Therefore, the phenomenology 
of the associated MD lacks consensus. Its 
clearer description will facilitate confident 
recognition and enable earlier immuno-
therapy administration in NMDAR-AbE.
Expert-rater descriptions remain the 
gold standard to define phenotypes in 
movement disorders. In this study, ratings 
from seven experts across 76 videos 




Autoimmune neurology researchers 
contributed 44 videos from 20 
patients who met diagnostic criteria 
for NMDAR-AbE.e1 A PubMed search 
for ‘anti-NMDAR encephalitis’ and 
‘NMDAR-antibody encephalitis’, plus 
associated references, revealed 32 videos 
from 14 subjects, in eight papers from 14 
subjects.3, e2–8 Clinical features, temporal 
progression, outcomes and investiga-
tion findings were collated from case 
note reviews by the researchers and from 
data in published papers. Twenty videos 
from 18 age-matched and sex-matched 
(age range 2–41 years, median 12, 50% 
female) disease controls were selected 
from the literature (online supplementary 
data).3e9–19
Movement disorder classification
Seven experts (KB, VF, AEL, TL, NN, 
KS and MT) established a consensus 
glossary of terms (online supplementary 
data, modified from Mohammed et al3). 
Subsequently, each expert blindly and 
independently rated 76 videos from 34 
patients with NMDAR-AbE (median two 
videos per patient, range 1–7) plus 20 
disease controls, using glossary-derived 
terms within a standardised data collec-
tion sheet (online supplementary data).
results
cohort characteristics
From the 34 patients, median age was 7 
years (range 0.2–32 years) and 59% were 
female. Consistent with this young cohort, 
6% (2/34) had ovarian teratomas. Peak 
modified Rankin Scale showed a severe 
illness (median 5; range 2–5), and, other 
than the prerequisite MD, the clinical 
features and investigation findings were 
in accordance with other series of patients 
with NMDAR-AbE (figure 1A–B).1 2 
Overall, the MD was an early feature of 
the disease (figure 1B) and, in addition to 
the known prolonged psychiatric symp-
toms, persisted for a median of 112.5 days 
(range 30–1482, figure 1C).
evaluation of videos
Videos were recorded at a median of 28 
days from symptom onset (range 1–690 
days). Across all videos, three principle 
dominant MDs were noted (figure 1D): 
dystonia (20%), chorea (20%) and stereo-
typies (19%). Other hyperkinetic phenom-
enologies included clonic perseveration 
(6%), ballism (6%), myoclonus (5%), 
tonic perseveration (3%) and tremor 
(1%). Hypokinetic terms included cata-
tonia (6%) and bradykinesia (5%). Three 
representative videos are presented in the 
online supplementary video 1-3.
Overall, fewer phenomenological terms 
were used to describe the MDs from 
disease controls (mean 1.9 per video, range 
1–4; online supplementary data) versus 
patients with NMDAR-AbE (mean 3.4 
per video, range 1–7; p<0.0001, Mann-
Whitney U-test). This complexity was 
consistent with the strong inter-rater reli-
ability across the 20 disease control videos 
in comparison to the 76 NMDAR-AbE 
videos, for the dominant phenomenology 
as dystonia (κ=0.65 vs  0.39, controls vs 
NMDAR-AbE), chorea (κ=0.63 vs  0.39) 
or stereotypies (κ=0.91 vs  0.22).
Analysis of the frequency of MDs 
within a single video in the patients 
with NMDAR-AbE revealed marked coex-
istence of chorea, dystonia and stereo-
typies (figure 1E and online supplementary 
figure 1). Indeed, 97% (33/34) of patients 
and 79% (60/76) of videos contained two 
of dystonia, chorea and stereotypies, with 
76% (26/34) of patients and 46% (35/76) 
of videos containing all three phenome-
nologies. Overall, very similar patterns 
were observed with inclusion of associated 
disorders (online supplementary figure 
2)3 and across ages and gender (data not 
shown).
temporal variability and regional 
distribution of the movement disorder
To explore these patterns over time, 
several patients were rated longitudi-
nally. Dystonia, stereotypies and chorea 
remained prominent but there was marked 
variability in the MD within an individual 
patient over the course of a single day 
and over a number of weeks (median=21 
days, range 0–360 days; online supple-
mentary figure 3). Finally, the anatomical 
distribution of these phenomenologies 
revealed similar ratings in the face, arm 
and leg (figure 1F).
dIscussIon
NMDAR-AbE is a severe yet treat-
able neurological disorder in which 
prompt administration of immunother-
apies improves outcomes.2 The MD is a 
common and well-emphasised feature of 
disease descriptions, yet until now lacked 
an expert-based gold-standard descrip-
tion.1–5 From this study, the MD was an 
early and persistent feature and, from 
a large collection of videos, it was char-
acterised by diverse, widely distributed 
hyperkinetic phenomenologies, with 
prominent dystonia, chorea and stereo-
typies, with almost complete absence 
of tremor and tics and a relative paucity 
of myoclonus. Furthermore, it was 
complex to describe using conventional 
MD terminology, yet the above features 
may help differentiate this mixed move-
ment disorder from important differen-
tial diagnoses in routine clinical practice 
including primary psychiatric disorders, 
childhood metabolic disturbances and 
drug intoxication. Indeed, the coexistence 
of widely distributed chorea, dystonia and 
stereotypies is rare in other neurological 
conditions (expert panel, unpublished 
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In this study, expert-rater feedback 
stated ‘our definition and description of 
hyperkinetic movements do not cover some 
of these patients’ and ‘reviewing all of these 
videotapes was a challenge particularly to 
preconceived and established phenomeno-
logical categorisations. Not infrequently 
I was dissatisfied with the final category 
that I chose’. This difficulty in classi-
fying patients with conventional terms is 
reflected in the inter-rater kappa statis-
tics and the greater variety of terms used 
to describe patients with NMDAR-AbE. 
These kappa values could be interpreted 
as reflecting variability between expert-
raters, but they showed good agreement 
across other varied control disorders 
and many terms are not interchangeable. 
However, potential study limitations 
include the lack of accompanying clinical 
histories and standardised video assess-
ments, the overall young age and marked 
disease severity, the surprisingly prolonged 
duration of the MD and an intrinsic 
bias towards recording the most unusual 
movements. Future extension studies 
could also incorporate a consecutive series 
of patients with a more exhaustive list of 
control mixed movement disorders.
In summary, this clinical constellation 
of phenomenologies, with the unusual 
triad of dystonia, stereotypies and chorea, 
should, in the correct clinical context, 
provide clinicians with greater confi-
dence in diagnosing this common cause 
of encephalitis, allowing earlier immu-
notherapy administration and improved 
patient outcomes.
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Figure 1  the clinical features and movement disorder evaluations in 34 patients with N-methyl-D-aspartate-antibody encephalitis (NMDAr-Abe). 
(A) Clinical and investigation findings across the 34 patients whose videos were rated. By definition, all patients had a movement disorder (MD) and 
other clinical and paraclinical features included psychiatric (n=33/34), cognitive (n=32/34), seizures (n=30/34), autonomic (n=17/34), abnormal 
electroencephalogram (n=28/30), abnormal cerebrospinal fluid (CSF) (n=19/33) and abnormal MrI (n=9/34). Abnormal CSF findings included any of 
pleocytosis, oligoclonal bands or raised protein. two ovarian teratomas were noted in postpubescent women (25 and 32 years). Overall, three cases were 
adults. (B) Symptom onset and offset in NMDAr-Abe: timings of onset (black) and offset (grey) of the main five symptom categories after first symptom (day 
1; median, minimum and maximum values displayed on box and whisker plot), (C) with a particular focus on the timing of the MD in individual patients. Full 
datasets were available from coauthors and denominators <34 represent variably reported details from the literature-derived videos. expert classification of 
phenomenology for 76 videos from patients with NMDAr-Abe (D–F). (D) Dystonia, chorea and stereotypies were the most commonly used terms. For the 
‘other’ category, raters used terms including: mutism, stupor, myorhythmia, myokymia, tics, opisthotonus, cerebellar syndrome/ataxia, orofacial dyskinesia, 
waxy flexibility, oculogyric crises, athetosis, agitation, seizure, startle and vocal perseveration. (e) the interactions between phenomenologies in NMDAr-
Abe with co-occurrence of stereotypies, chorea and dystonia shown in a Circos plot,e20 based on a co-occurrence matrix within single video ratings. (F) 
Stereotypies, chorea and dystonia were equally represented in the face, arm and leg, respectively.
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